CD19-CAR-DNT cells

BIOLOGICAL2 trials

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University, RenJi Hospital

Conditions

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisB-cell Non-Hodgkin's LymphomaIdiopathic Inflammatory MyopathiesSystemic Lupus ErythematosusSystemic Sclerosis

Phase 1

Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityB-cell Non-Hodgkin's Lymphoma

Start: 2022-06-15End: 2025-06-30Target: 12Updated: 2022-07-12

Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases

RecruitingNCT06316076

RenJi HospitalAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Idiopathic Inflammatory Myopathies, Systemic Lupus Erythematosus +1

Start: 2023-10-30End: 2026-06-30Target: 48Updated: 2024-03-18

Related Papers

CD19-CAR-DNT cells (RJMty19) in patients with relapsed or refractory large B-cell lymphoma: a phase 1, first-in-human study.

2024-02-2915 citations

A Phase 1 Study of RJMty19: Anti-CD19 Humanized CAR-Engineered Allogeneic Double Negative T Cells in Adults with B-Cell Non-Hodgkin's Lymphoma

Blood2023-11-026 citations